Fundamental Analysis of NewAmsterdam Pharma Co. NV - Growth / Value Index
NAMS - Valuation Highlights
Valuation Analysis
Tsr Value Index - Very Poor Score of 5.00
Price to Book Ratio of 11.68 suggesting that it is very expensive
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | -15.43 | -8.74 | 55.39 % | |
| Price to Book | 10.90 | 5.36 | 69.88 % | 3.74 |
| Price to Sales | 133.91 | 109.75 | 599.70 % | |
| Enterprise Value to EBITDA Multiple | -21.07 | -7.03 | 49.95 % |
NAMS - Profitability Highlights
Profitability Analysis
Tsr Profitability Index - Very Poor Score of 5.00
Piotroski F Score - Very Poor Value of 1.0
Very Low Dividend Yield of 0 %
Negative Net profit for last two years
In the last three years, the company has given poor Net Margin
In the last three years, the company has given poor Returns on Equity
In the last three years, the company has given poor Returns on Assets
Negative Net Margin MRQ
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | -70.67 | -61.35 | -280.86 % | -22.77 |
| Return On Asset | -58.98 | -50.98 | -247.18 % | -19.20 |
| Net Profit Margin | -867.96 | -1255.76 | -1468.66 % | -6692.86 |
| Operating Profit Margin | -545.25 | -1298.56 | -18091.02 % | -3960.17 |
| EBITDA Margin | -542.09 | -1218.13 | -1428.37 % | -3960.17 |
Highlights
| Market Cap | 1687.23 M |
| Enterprise Value | 1346.84 M |
| Price/Book TTM | 10.90 |
| Outstanding Share | 89985.80 K |
| Float/ Outstanding Share | 33.57% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 0 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 1.00 |
| Altman Z Score | 15.40 |
| Sloan Ratio | -0.103 |
| Peter Lynch Fair Value | 0 |
NAMS - Growth Highlights
Growth Analysis
YoY Net Margin Jump by 1468.66%
Tsr Growth Index - Very Poor Score of 10.09
Companies' sales dropped by 85.55 % from last year
Operating Cash Flow decreasing for last 3 year
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 11792.45 K | 85.55 % | % |
| Gross Profit | 11792.44 K | 85.55 % | % |
| EBITDA | -63925.25 K | 120.87 % | % |
| Net Profit | -102354.00 K | 126.69 % | % |
| EPS | -1.22 | 124.19 % | NA |
NAMS - Stability Highlights
Stability Analysis
Altman Z Score of 16.63 suggests good Stability
Cash ratio of 6.82
Company is unable to generate enough free cash to support the business.
Interest Coverage of 0
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.0002 | 62.59 % | 0.0001 |
| Cash Ratio | 6.82 | -44.83 % | |
| Quick Ratio | 6.99 | -44.70 % | 8.17 |
| Shareholders Equity | 83.09 | -8.84 % | |
| Debt to EBITDA | -0.0003 | 56.18 % |
Historical Valuation Ratios of NewAmsterdam Pharma Co. NV
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of NewAmsterdam Pharma Co. NV
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of NewAmsterdam Pharma Co. NV
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of NewAmsterdam Pharma Co. NV
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)